Clinical Trials on Cancers Expressing HER-2 and/or CEA in Ireland

Total 98 results

Novartis Pharmaceuticals

Completed

A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy

HR+/HER2- Advanced or Metastatic Breast Cancer

Ireland
QuantumLeap Healthcare Collaborative

Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program (PRE-I-SPY-PI)

Solid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Elevated CA15-3 or CEA or CA27-29

United States, Puerto Rico, Guam
Brown University
AstraZeneca

Recruiting

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Esophageal Cancer | Esophageal Adenocarcinoma | HER-2 Protein Overexpression | Gastroesophageal-junction Cancer

United States
Cancer Trials Ireland

Completed

Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer

Breast Cancer | HER2 Positive Breast Cancer | HER2 Negative Breast Cancer

Ireland
Cancer Trials Ireland

Terminated

CharactHer. ICORG 12-09, V3

HER2-positive Breast Cancer | TNM Stage II-IV Breast Cancer

Ireland, Italy
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Italy, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
Genentech, Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Korea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
Galena Biopharma, Inc.

Completed

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence (PRESENT)

Breast Cancer With Low to Intermediate HER2 Expression

United States, United Kingdom, France, Israel, Germany, Canada, Russian Federation, Romania, Bulgaria, Czech Republic, Hungary, Poland, Ukraine
Cancer Trials Ireland

Recruiting

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

HER2-positive Breast Cancer

Ireland
Cancer Trials Ireland

Terminated

The Myocet/Lapatinib Study. ICORG 10-03, V5

Her2 Positive Metastatic Breast Cancer

Ireland
Cancer Trials Ireland

Terminated

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer (Panthera)

Metastatic Breast Cancer | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Cancer

Ireland, Spain
MacroGenics

Completed

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA)

HER-2 Positive Breast Cancer | Metastatic Neoplasm

United States, Spain, Italy, Canada, Israel, Belgium, Germany, Czechia, Austria, Korea, Republic of, Denmark, United Kingdom, Portugal, France, Poland, Netherlands, Finland, Puerto Rico
European Organisation for Research and Treatment...
Breast International Group; Menarini Group

Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (TREAT ctDNA)

Stage IIB Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Stage III Breast Cancer

Belgium, Italy, Ireland, France, Germany
Cancer Trials Ireland

Completed

Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) (Panther)

HER2 Positive Breast Cancer

Ireland
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United Kingdom, Korea, Republic of, Australia, United States, Spain
Janssen Research & Development, LLC

Completed

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Postmenopausal | Metastatic ER+ Her2- Breast Cancer

United States, France, Ukraine, United Kingdom, Belgium, Spain, Netherlands, Korea, Republic of, Russian Federation, Poland, Luxembourg, Ireland
Syndax Pharmaceuticals

Completed

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

ER+ Breast Cancer

Ireland, United Kingdom
Daiichi Sankyo

Completed

EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan (EUROPA T-DXd)

HER2-positive Breast Cancer

Spain, Ireland, Italy
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone... and other conditions

United States
Puma Biotechnology, Inc.

Terminated

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations (SUMMIT)

Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

France, United States, Spain, Belgium, United Kingdom, Serbia, Australia, Israel, Canada, Denmark, Ireland, Italy, Korea, Republic of
Dana-Farber Cancer Institute
MacroGenics; Translational Breast Cancer Research Consortium

Recruiting

MARGetuximab Or Trastuzumab (MARGOT) (MARGOT)

Breast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage III Breast Cancer

United States
Puma Biotechnology, Inc.

Terminated

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

Metastatic Cervical Cancer | Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Spain, Israel, United States, Serbia, France, Ireland, Italy
University of Washington
National Cancer Institute (NCI)

Completed

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

United States
Hoffmann-La Roche

Completed

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Cardiovascular Disease, Diabetes Mellitus Type 2

Germany, Spain, Korea, Republic of, United States, Colombia, Mexico, Hungary, Canada, Austria, Estonia, Malaysia, Australia, Poland, Thailand, Czech Republic, Latvia, Italy, Romania, Russian Federation, Chile, Lithuania, Sweden, United... and more
Dana-Farber Cancer Institute
Genentech, Inc.

Recruiting

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Breast Cancer | HER2-positive Breast Cancer

United States
German Breast Group
Pfizer; AGO Study Group; Breast International Group; NSABP Foundation Inc

Completed

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery (PENELOPE-B)

Breast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG Score

United States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
Queen Mary University of London
Astellas Pharma Inc

Unknown

Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB)

Primary Breast Cancer ER+ve | Primary Breast Cancer AR+ve TNBN

Germany, United Kingdom, Spain, United States, Ireland
National Cancer Institute (NCI)

Active, not recruiting

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Unresectable Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Metastatic HER2-Negative Breast Carcinoma | Unresectable HER2-Negative Breast Carcinoma | Locally Advanced HER2-Negative...

United States
German Breast Group
Gilead Sciences; ETOP IBCSG Partners Foundation; UNICANCER; Austrian Breast & Colorectal... and other collaborators

Recruiting

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (SASCIA)

Triple Negative Breast Cancer | HER2-negative Breast Cancer

Spain, France, Germany, Austria, Belgium, Ireland, Italy, Switzerland
NRG Oncology
National Cancer Institute (NCI); Alliance for Clinical Trials in Oncology; Eastern... and other collaborators

Recruiting

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer (HERO)

HER2-positive Breast Cancer

United States, Puerto Rico
Puma Biotechnology, Inc.

Completed

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)

HER2+ Metastatic Breast Cancer (MBC)

United States, Canada, Spain, Singapore, Korea, Republic of, Taiwan, United Kingdom, Israel, Australia, Japan, Hong Kong, Finland, Ireland, Italy, France, Portugal, Germany, Sweden, Belgium, Brazil, Czechia, Switzerland, Argentina, Au... and more
Pfizer

Active, not recruiting

A Study of PF-06873600 in People With Cancer

HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer

United States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
Children's Cancer and Leukaemia Group

Unknown

Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney

Kidney Cancer

United Kingdom, Ireland
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)

HER2 Positive Breast Cancer

United States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
National Cancer Institute (NCI)

Completed

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Bayer; United States Department of Defense; Canadian...

Terminated

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Node Positive HER2 Negative Breast Cancer

United States, Canada, Puerto Rico, Guam
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | HER2/Neu Positive

United States, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic HER2-Negative Breast Carcinoma

United States
Daiichi Sankyo, Inc.
AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...

Active, not recruiting

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

HER2-Positive Primary Breast Cancer | Residual Invasive Breast Cancer

United States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
National Cancer Institute (NCI)

Completed

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Recurrent Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | HER2 Positive Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
Puma Biotechnology, Inc.

Completed

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Early Stage HER2+ Breast Cancer

Spain, United States, France, Australia, Germany, Austria, Canada
aTyr Pharma, Inc.

Completed

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

SARS-CoV-2 (COVID-19) Severe Pneumonia

United States, Puerto Rico
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
Brown University
Taiho Oncology, Inc.

Recruiting

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Soft Tissue Sarcoma | Advanced Breast Cancer | SCLC | Bladder Cancer | Endometrial Cancer | Treatment-Refractory Solid Tumors | Retinoblastoma Deficiency

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Suspended

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Invasive Breast Carcinoma | HER2/Neu Negative | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
BicycleTx Limited

Recruiting

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Head and Neck Cancer | Ovarian Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Solid Tumor Historically Known for High EphA2 Expression | Urothelial Cancer | Gastric/Upper Gastrointestinal Cancer

United States, Belgium, Korea, Republic of, Spain, United Kingdom
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

HER2/Neu Negative | Estrogen Receptor-positive Breast Cancer | Stage IV Breast Cancer AJCC v6 and v7

United States
ModernaTX, Inc.

Terminated

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Ovarian Cancer | Relapsed/Refractory Solid Tumor Malignancies or Lymphoma

United States

Clinical Trials on Cancers Expressing HER-2 and/or CEA in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations